BOARD OF DIRECTORS
Robert E. Cawthorn
Mr. Cawthorn is a former Managing Director of Global Health Care Partners of DLJ Merchant Banking Partners, having retired in 2001. Mr. Cawthorn served as Chief Executive Officer of Rhône-Poulenc Rorer Inc. in May 1995 and as Chairman in May 1996, after nearly four decades in the pharmaceutical, biotechnology, and animal health industries. Mr. Cawthorn was an executive with Pfizer International for seventeen years and was the first president of Biogen Inc. (now Biogen/Idec Inc.) before joining Rorer Group in 1982. He is credited with transforming Rorer into a major research-driven pharmaceutical company, largely through acquisitions and mergers, culminating in the successful merger that created Rhône-Poulenc Rorer in 1990. Mr. Cawthorn is Chairman of Actelion Ltd. and also serves as a director of The March Group, NextPharm Technologies, and Leerink Swann & Co. Mr. Cawthorn is a graduate of Cambridge University, England.
Jack W. Schuler
Mr. Schuler joined the Biodesix Board of Directors in June 2008. He also sits on the Board of Directors of Stericycle, Inc. From January 1987 to August 1989, Mr. Schuler served as President and Chief Operating Officer of Abbott Laboratories, a diversified health care company which he joined in 1972 and where he held a number of management and marketing positions, also serving as a director from April 1985 to August 1989. He served as Chairman of the Board of Directors of Ventana Medical Systems, Inc. prior to its acquisition by Roche in February 2008, and as a director of Medtronic, Inc., and Quidel Corporation, a leader in point-of-care rapid diagnostic tests. He is the co-founder of Crabtree Partners, a private investment partnership in Lake Forest, Illinois, which was formed in June 1995. Mr. Schuler received a B.S. degree in Mechanical Engineering from Tufts University and an M.B.A. degree from the Stanford University Graduate School of Business Administration.
Mr. Patience joined the Biodesix Board of Directors in June 2008. Mr. Patience also serves as a director of Stericycle, Inc. and has done so since its incorporation in March 1989. He is a co-founder and partner of Crabtree Partners, a private investment partnership in Lake Forest, Illinois, which was formed in June 1995. From January 1988 to March 1995, Mr. Patience was a general partner of Marquette Venture Partners, L.P., a venture capital fund which he co-founded. Mr. Patience was Vice Chairman of Ventana Medical Systems, Inc. prior to its acquisition by Roche in February 2008. Mr. Patience received B.A. and Bachelor of Law degrees from the University of Sydney in Sydney, Australia, and an M.B.A. degree from the Wharton School of Business of the University of Pennsylvania.
Mr. Brunel has been involved in enterprise software for over 25 years and has been involved in molecular diagnostics since 2000. Mr. Brunel was a founder and CEO of Unidata, Inc. when it merged with Vmark Software to create Ardent Software, Inc., where he was President and COO. He was also a member of the Board of Ardent until it was sold to Informix in 1999. Mr. Brunel was also a co-founder and President of SomaLogic, Inc., a company focused on creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. Mr. Brunel is also on the board of Anark Corporation and Xyleme, Inc.
Mark C. Miller
Mr. Miller joined the Biodesix Board of Directors in 2011. He has served as the Chief Executive Officer and a director of Stericycle, Inc. since May 1992, and became Chairman of the Board of Directors in August 2008. From May 1989 until joining Stericycle, Mr. Miller was vice president for the Pacific, Asia and Africa in the international division of Abbott Laboratories, a diversified health care company, which he joined in 1976 and where he held a number of management and marketing positions. Mr. Miller formerly served as a director of Ventana Medical Systems, Inc., a developer and supplier of automated diagnostic systems. He received a B.S. degree in computer science from Purdue University, where he graduated Phi Beta Kappa. Mr. Miller was selected by Morningstar, Inc. as its “2009 CEO of the Year.”
Dr. Strobeck joined the Biodesix Board in January 2012. From June 2008 to October 2011, Dr. Strobeck was a Partner, Member of the Management Committee and Member of the Advisory Board of Westfield Capital Management, an investment firm with approximately $15 billion in assets under management. Dr. Strobeck organized and completed the repurchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the investment team. Dr. Strobeck previously served as a Director of Metabolix Inc., Collegium Pharmaceuticals and Precision Dermatology. Dr. Strobeck received a B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.